A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.
Kura Oncology, Inc.
Bristol-Myers Squibb
Mirati Therapeutics Inc.
Incyte Corporation
Bristol-Myers Squibb
Mirati Therapeutics Inc.
Mirati Therapeutics Inc.